A study of MCLA-158 in the treatment of colorectal cancer

Trial Profile

A study of MCLA-158 in the treatment of colorectal cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs MCLA 158 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 04 Jan 2018 According to a Merus media release, company got an CTA approval to initiate this trial in Belgium first quarter of 2018. Also, company plans to file an IND for MCLA-158 with the U.S. FDA in the first quarter of 2018.
    • 28 Apr 2017 According to a Merus media release, company expects to file a CTA for this trial by the end of 2017.
    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top